Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury

Mitchell S. Anscher, Jennifer Garst, Lawrence B. Marks, Nicole Larrier, Frank Dunphy, James E. Herndon, Robert Clough, Christine Marino, Zeljko Vujaskovic, Sumin Zhou, Mark W. Dewhirst, Timothy D. Shafman, Jeffrey Crawford

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelbine plus thoracic radiotherapy. Methods and Materials: Eligible patients had inoperable Stage III non-small-cell lung cancer, a Karnofsky Performance Status ≥70, and life expectancy ≥6 months. Patients underwent pretreatment evaluation of lung function. Radiotherapy consisted of 66 Gy in 6.5 weeks. Vinorelbine was administered i.v. (5 mg/m2) 3 times per week just before radiotherapy. Thalidomide was begun at 50 mg, p.o., on day 1 of chemoradiotherapy and continued once daily for 6 months. Side effects were scored using National Cancer Institute Common Toxicity Criteria. Results: Ten patients were enrolled. Of the first 6 patients, 2 developed major thrombotic events that were believed to be possibly related to thalidomide. The study was suspended and modified to require prophylactic anticoagulation. Of the last 4 patients, 2 developed dose-limiting toxicity attributable to thalidomide; both patients required a dose reduction of thalidomide to <50 mg/day. Because the drug is not available in an oral product providing <50 mg/day, the study was closed. Conclusions: The combination of thalidomide concurrently with thoracic radiotherapy and vinorelbine resulted in excessive toxicity.

Original languageEnglish (US)
Pages (from-to)477-482
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue number2
DOIs
StatePublished - Oct 1 2006

Fingerprint

Thalidomide
Angiogenesis Inhibitors
Lung Injury
lungs
Radiation
radiation
radiation therapy
Radiotherapy
toxicity
Chemoradiotherapy
dosage
Thorax
cancer
Karnofsky Performance Status
Maximum Tolerated Dose
National Cancer Institute (U.S.)
Life Expectancy
Non-Small Cell Lung Carcinoma
pretreatment
drugs

Keywords

  • Complications
  • Cytokines
  • Non-small-cell lung cancer
  • Thalidomide

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. / Anscher, Mitchell S.; Garst, Jennifer; Marks, Lawrence B.; Larrier, Nicole; Dunphy, Frank; Herndon, James E.; Clough, Robert; Marino, Christine; Vujaskovic, Zeljko; Zhou, Sumin; Dewhirst, Mark W.; Shafman, Timothy D.; Crawford, Jeffrey.

In: International Journal of Radiation Oncology Biology Physics, Vol. 66, No. 2, 01.10.2006, p. 477-482.

Research output: Contribution to journalArticle

Anscher, MS, Garst, J, Marks, LB, Larrier, N, Dunphy, F, Herndon, JE, Clough, R, Marino, C, Vujaskovic, Z, Zhou, S, Dewhirst, MW, Shafman, TD & Crawford, J 2006, 'Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury', International Journal of Radiation Oncology Biology Physics, vol. 66, no. 2, pp. 477-482. https://doi.org/10.1016/j.ijrobp.2006.05.031
Anscher, Mitchell S. ; Garst, Jennifer ; Marks, Lawrence B. ; Larrier, Nicole ; Dunphy, Frank ; Herndon, James E. ; Clough, Robert ; Marino, Christine ; Vujaskovic, Zeljko ; Zhou, Sumin ; Dewhirst, Mark W. ; Shafman, Timothy D. ; Crawford, Jeffrey. / Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 66, No. 2. pp. 477-482.
@article{c0e35cd7c9a34d798a7adb12f9ab1c53,
title = "Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury",
abstract = "Purpose: Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelbine plus thoracic radiotherapy. Methods and Materials: Eligible patients had inoperable Stage III non-small-cell lung cancer, a Karnofsky Performance Status ≥70, and life expectancy ≥6 months. Patients underwent pretreatment evaluation of lung function. Radiotherapy consisted of 66 Gy in 6.5 weeks. Vinorelbine was administered i.v. (5 mg/m2) 3 times per week just before radiotherapy. Thalidomide was begun at 50 mg, p.o., on day 1 of chemoradiotherapy and continued once daily for 6 months. Side effects were scored using National Cancer Institute Common Toxicity Criteria. Results: Ten patients were enrolled. Of the first 6 patients, 2 developed major thrombotic events that were believed to be possibly related to thalidomide. The study was suspended and modified to require prophylactic anticoagulation. Of the last 4 patients, 2 developed dose-limiting toxicity attributable to thalidomide; both patients required a dose reduction of thalidomide to <50 mg/day. Because the drug is not available in an oral product providing <50 mg/day, the study was closed. Conclusions: The combination of thalidomide concurrently with thoracic radiotherapy and vinorelbine resulted in excessive toxicity.",
keywords = "Complications, Cytokines, Non-small-cell lung cancer, Thalidomide",
author = "Anscher, {Mitchell S.} and Jennifer Garst and Marks, {Lawrence B.} and Nicole Larrier and Frank Dunphy and Herndon, {James E.} and Robert Clough and Christine Marino and Zeljko Vujaskovic and Sumin Zhou and Dewhirst, {Mark W.} and Shafman, {Timothy D.} and Jeffrey Crawford",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2006.05.031",
language = "English (US)",
volume = "66",
pages = "477--482",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury

AU - Anscher, Mitchell S.

AU - Garst, Jennifer

AU - Marks, Lawrence B.

AU - Larrier, Nicole

AU - Dunphy, Frank

AU - Herndon, James E.

AU - Clough, Robert

AU - Marino, Christine

AU - Vujaskovic, Zeljko

AU - Zhou, Sumin

AU - Dewhirst, Mark W.

AU - Shafman, Timothy D.

AU - Crawford, Jeffrey

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Purpose: Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelbine plus thoracic radiotherapy. Methods and Materials: Eligible patients had inoperable Stage III non-small-cell lung cancer, a Karnofsky Performance Status ≥70, and life expectancy ≥6 months. Patients underwent pretreatment evaluation of lung function. Radiotherapy consisted of 66 Gy in 6.5 weeks. Vinorelbine was administered i.v. (5 mg/m2) 3 times per week just before radiotherapy. Thalidomide was begun at 50 mg, p.o., on day 1 of chemoradiotherapy and continued once daily for 6 months. Side effects were scored using National Cancer Institute Common Toxicity Criteria. Results: Ten patients were enrolled. Of the first 6 patients, 2 developed major thrombotic events that were believed to be possibly related to thalidomide. The study was suspended and modified to require prophylactic anticoagulation. Of the last 4 patients, 2 developed dose-limiting toxicity attributable to thalidomide; both patients required a dose reduction of thalidomide to <50 mg/day. Because the drug is not available in an oral product providing <50 mg/day, the study was closed. Conclusions: The combination of thalidomide concurrently with thoracic radiotherapy and vinorelbine resulted in excessive toxicity.

AB - Purpose: Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelbine plus thoracic radiotherapy. Methods and Materials: Eligible patients had inoperable Stage III non-small-cell lung cancer, a Karnofsky Performance Status ≥70, and life expectancy ≥6 months. Patients underwent pretreatment evaluation of lung function. Radiotherapy consisted of 66 Gy in 6.5 weeks. Vinorelbine was administered i.v. (5 mg/m2) 3 times per week just before radiotherapy. Thalidomide was begun at 50 mg, p.o., on day 1 of chemoradiotherapy and continued once daily for 6 months. Side effects were scored using National Cancer Institute Common Toxicity Criteria. Results: Ten patients were enrolled. Of the first 6 patients, 2 developed major thrombotic events that were believed to be possibly related to thalidomide. The study was suspended and modified to require prophylactic anticoagulation. Of the last 4 patients, 2 developed dose-limiting toxicity attributable to thalidomide; both patients required a dose reduction of thalidomide to <50 mg/day. Because the drug is not available in an oral product providing <50 mg/day, the study was closed. Conclusions: The combination of thalidomide concurrently with thoracic radiotherapy and vinorelbine resulted in excessive toxicity.

KW - Complications

KW - Cytokines

KW - Non-small-cell lung cancer

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=33748299333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748299333&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.05.031

DO - 10.1016/j.ijrobp.2006.05.031

M3 - Article

C2 - 16904841

AN - SCOPUS:33748299333

VL - 66

SP - 477

EP - 482

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -